<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674700</url>
  </required_header>
  <id_info>
    <org_study_id>VO57.07</org_study_id>
    <nct_id>NCT00674700</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis</brief_title>
  <official_title>A Randomized, DBPC, Multi-national Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of two doses of sublingual immunotherapy
      (SLIT) administered as allergen-based tablets once daily over a period of 12 months compared
      to placebo, for reduction of allergic rhinitis symptoms and rescue medication usage
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic rhinitis is a high-prevalence disease in many developed countries, affecting about
      10 to 20% of the general population. House dust mite allergens are known to cause perennial
      allergic rhinitis.

      In designing the present study, the guidelines proposed by the World Allergy Organization
      (WAO) task force for methodology of immunotherapy studies have been taken into consideration.

      After a 2-month screening period, patients will be administered the dose of 300 IR- or 500
      IR-house dust mite allergen-based tablets or placebo for a period of 12 months. The
      carry-over effect will be evaluated after a treatment-free follow up period of 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period</measure>
    <time_frame>Last 3 months of Year 1</time_frame>
    <description>The AAdSS is derived from the daily Rhinoconjunctivitis Total Symptom Scores (RTSS), based on the severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).
It ranges from 0 to 12, the higher the score the more severe the rhinitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Rhinitis Total Symptom Score (ARTSS)</measure>
    <time_frame>Last 3 months of Year 1</time_frame>
    <description>The Rhinitis Total Symptom Score (RTSS) evaluates the presence and severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion (absence of symptom (0), mild symptom (1), moderate symptom (2), severe symptom (3)). It ranges from 0 to 12, the higher the score the more severe the rhinitis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>300 IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 IR house dust mites allergen extract tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 IR house dust mites allergen extract tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 IR house dust mites allergen extract tablet</intervention_name>
    <description>One sublingual tablet daily for one year</description>
    <arm_group_label>300 IR</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 IR house dust mites allergen extract tablet</intervention_name>
    <description>One sublingual tablet daily for one year</description>
    <arm_group_label>500 IR</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>One sublingual tablet daily for one year</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sublingual placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female outpatients aged 18 to 50 years (inclusive).

          2. Patients who have been informed of the nature and aims of the study and have given
             their written consent

          3. Patients must be in general good health as determined by past medical history,
             physical examination and safety laboratory tests.

          4. Female patients of childbearing potential are eligible

          5. Negative urine pregnancy test on female patients of childbearing potential.

          6. House dust mite-related allergic rhinitis for at least 1 year.

          7. Sensitised to D. pteronyssinus or D. farinae (positive SPT with wheal diameter greater
             than 3 mm and a specific IgE level ≥ 0.7 kU/L).

          8. Baseline ARTSS &gt; 5 (after completion of the 7-day daily record card).

          9. Patients who are willing to comply with the protocol.

         10. Patients who are able to understand the information given and the text of the consent
             form, and who are able to complete the daily record card and the RQLQ.

        Exclusion Criteria:

          1. Whatever the considered allergens, co-sensitisation leading to clinically relevant
             allergic rhinitis, sinusitis, conjunctivitis or asthma likely to significantly change
             the symptoms of the patient throughout the study (that means patient symptomatic to
             another allergen than house dust mites).

          2. Patients with any nasal condition that could confound the efficacy or safety
             assessments (for example nasal polyposis).

          3. Patients sensitised to cat or dog allergens and living with these animals at home.

          4. Pregnant, breast-feeding / lactating or sexually active women of childbearing
             potential who are not using a medically accepted contraceptive method.

          5. Asthma requiring treatment other than beta-2 inhaled agonists. Patients with
             intermittent asthma not necessitating inhaled or systemic corticoid treatment may be
             included (corresponding to the Global Initiative for Asthma [GINA] Step 1).

          6. Patients treated with systemic, nasal or inhaled steroids (whatever the indication)
             within 4 weeks before Visit 1.

          7. Patients treated with long acting systemic steroids (whatever the indication) within
             12 weeks before Visit 1 and before Visit 2.

          8. FEV1 &lt; 80% of predicted value at Visit 1.

          9. Patients who received allergy specific immunotherapy for house dust mites in the last
             10 years.

         10. Patients at risk of non-compliance.

         11. Participation in any clinical study within the 12 weeks before Visit 1.

         12. Investigators, co-investigators, as well as their children or spouses and all the
             study collaborators should not be enrolled in the study.

         13. Any change in environmental measures for allergen avoidance during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Christian BERGMANN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Allergie-Centrum-Charité / ECARF</affiliation>
  </overall_official>
  <results_reference>
    <citation>Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, Nguyen H, Montagut A, Zeldin RK. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014 Jun;133(6):1608-14.e6. doi: 10.1016/j.jaci.2013.11.012. Epub 2013 Dec 31.</citation>
    <PMID>24388010</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <results_first_submitted>January 25, 2016</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2016</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>House dust mites allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient First Visit 12 OCT 2007, Last Patient Last Visit 01 FEB 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>300 IR</title>
          <description>300 IR house dust mites allergen extract tablet</description>
        </group>
        <group group_id="P2">
          <title>500 IR</title>
          <description>500 IR house dust mites allergen extract tablet</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 2 Follow-up Without Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set included all participants who received at least one dose of the investigational product and had at least one Adjusted Symptom Score evaluation in the year.</population>
      <group_list>
        <group group_id="B1">
          <title>300 IR</title>
          <description>300 IR house dust mites allergen extract tablet</description>
        </group>
        <group group_id="B2">
          <title>500 IR</title>
          <description>500 IR house dust mites allergen extract tablet</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="163"/>
            <count group_id="B4" value="466"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="8.52"/>
                    <measurement group_id="B2" value="30.1" spread="8.43"/>
                    <measurement group_id="B3" value="30.0" spread="8.96"/>
                    <measurement group_id="B4" value="29.7" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period</title>
        <description>The AAdSS is derived from the daily Rhinoconjunctivitis Total Symptom Scores (RTSS), based on the severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).
It ranges from 0 to 12, the higher the score the more severe the rhinitis.</description>
        <time_frame>Last 3 months of Year 1</time_frame>
        <population>The Full Analysis Set included all participants who received at least one dose of the investigational product and had at least one Adjusted Symptom Score evaluation in the year.</population>
        <group_list>
          <group group_id="O1">
            <title>300 IR</title>
            <description>300 IR house dust mites allergen extract tablet</description>
          </group>
          <group group_id="O2">
            <title>500 IR</title>
            <description>500 IR house dust mites allergen extract tablet</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period</title>
          <description>The AAdSS is derived from the daily Rhinoconjunctivitis Total Symptom Scores (RTSS), based on the severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).
It ranges from 0 to 12, the higher the score the more severe the rhinitis.</description>
          <population>The Full Analysis Set included all participants who received at least one dose of the investigational product and had at least one Adjusted Symptom Score evaluation in the year.</population>
          <units>Units on a scale (range: 0 to 12)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="0.224"/>
                    <measurement group_id="O2" value="3.09" spread="0.230"/>
                    <measurement group_id="O3" value="3.87" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0066</p_value>
            <p_value_desc>main effects = treatment and pools of study centers, Covariates = age, gender, asthma status, sensitization status and baseline ARTSS</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>main effects= treatment and pools of study centers, Covariates = age, gender, asthma status, sensitization status and baseline ARTSS</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rhinitis Total Symptom Score (ARTSS)</title>
        <description>The Rhinitis Total Symptom Score (RTSS) evaluates the presence and severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion (absence of symptom (0), mild symptom (1), moderate symptom (2), severe symptom (3)). It ranges from 0 to 12, the higher the score the more severe the rhinitis.</description>
        <time_frame>Last 3 months of Year 1</time_frame>
        <population>The Full Analysis Set included all participants who received at least one dose of the investigational product and had at least one Adjusted Symptom Score evaluation in the year.</population>
        <group_list>
          <group group_id="O1">
            <title>300 IR</title>
            <description>300 IR house dust mites allergen extract tablet</description>
          </group>
          <group group_id="O2">
            <title>500 IR</title>
            <description>500 IR house dust mites allergen extract tablet</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rhinitis Total Symptom Score (ARTSS)</title>
          <description>The Rhinitis Total Symptom Score (RTSS) evaluates the presence and severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion (absence of symptom (0), mild symptom (1), moderate symptom (2), severe symptom (3)). It ranges from 0 to 12, the higher the score the more severe the rhinitis.</description>
          <population>The Full Analysis Set included all participants who received at least one dose of the investigational product and had at least one Adjusted Symptom Score evaluation in the year.</population>
          <units>Units on a scale (range: 0 to 12)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="0.178"/>
                    <measurement group_id="O2" value="2.72" spread="0.183"/>
                    <measurement group_id="O3" value="3.32" spread="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0086</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the Year 1 with treatment and during the follow-up year without treatment. Results are provided here for the Year 1.</time_frame>
      <desc>Safety variables were adverse events (AEs) monitored throughout the study and data from physical examinations and clinical laboratory assessments.</desc>
      <group_list>
        <group group_id="E1">
          <title>300 IR</title>
          <description>300 IR house dust mites allergen extract tablet</description>
        </group>
        <group group_id="E2">
          <title>500 IR</title>
          <description>500 IR house dust mites allergen extract tablet</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <description>Reported as not related to the study drug.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <description>Reported as not related to the study drug.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <description>Reported as not related to the study drug.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <description>Reported as not related to the study drug.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <description>Reported as not related to the study drug.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Vaginal laceration</sub_title>
                <description>Reported as not related to the study drug.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Oedema mouth</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michel Roux, Medical Director</name_or_title>
      <organization>Stallergenes</organization>
      <phone>+33 1 55 59 2970</phone>
      <email>mroux@stallergenes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

